IL2 and Kaposi's sarcoma: Furthermore, a demonstrated activity of IM862 in AIDS-related Kaposi's sarcoma (Tulpule et al, 2000) together with minimal toxicity, especially with regard to the many side effects encountered with IL-2 and IFNα, prompted us to initiate this phase II trial.